Clinical Trial Update: Danicopan Early Access Program

View source ↗

Summary

An early access program for danicopan is described for patients with paroxysmal nocturnal hemoglobinuria (PNH), including those with extravascular hemolysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Danicopan (danicopan)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria, PNH | Status: AVAILABLE